BNP Paribas Financial Markets Makes New $1.58 Million Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

BNP Paribas Financial Markets bought a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 66,998 shares of the company’s stock, valued at approximately $1,578,000.

Several other large investors have also recently modified their holdings of the stock. abrdn plc purchased a new position in Dyne Therapeutics during the 4th quarter valued at $608,000. Raymond James Financial Inc. purchased a new position in Dyne Therapeutics during the 4th quarter valued at $2,340,000. Barclays PLC boosted its holdings in Dyne Therapeutics by 162.2% during the 3rd quarter. Barclays PLC now owns 207,309 shares of the company’s stock valued at $7,446,000 after acquiring an additional 128,246 shares during the period. Schroder Investment Management Group boosted its holdings in Dyne Therapeutics by 63.3% during the 4th quarter. Schroder Investment Management Group now owns 147,002 shares of the company’s stock valued at $3,477,000 after acquiring an additional 56,961 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in Dyne Therapeutics by 54.5% during the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company’s stock valued at $913,000 after acquiring an additional 13,677 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $11.83 on Monday. The stock has a market capitalization of $1.34 billion, a P/E ratio of -3.32 and a beta of 1.19. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45. The business has a fifty day moving average price of $10.36 and a 200 day moving average price of $17.35.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on DYN. JPMorgan Chase & Co. dropped their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, March 21st. Piper Sandler dropped their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. HC Wainwright lowered their target price on Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a report on Friday, May 9th. Finally, Scotiabank initiated coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.85.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders sold 6,237 shares of company stock worth $77,760 in the last three months. 14.14% of the stock is owned by insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.